- Solve real problems with our hands-on interface
- Progress from basic puts and calls to advanced strategies
Interactive Options Course
Posted July 25, 2025 at 9:30 am
We cover two Large Cap ‘Expensive but Worth It’ U.S. names this week, TRV and MLI. The firms were both upgraded from ‘Hold’ to ‘Buy’ in the U.S.-relative PRVitframework last Friday and yesterday, respectively, driven by improvements in
Quality (P-R). TRV’s earnings beat estimates, benefiting from effective underwriting and portfolio management. MLI also posted strong numbers on Monday with EVA Margin inflecting upwards after eight consecutive quarters of contraction.
The Health Care sector has slipped from attractive to neutral in the PRVit model. The Providers & Services and Pharmaceuticals industries are the key bright spots for the sector in the Global universe. Within each section of this report, we provide an overview of the industry’s profitability, its market-implied expectations for growth, and a list of companies within the industry.
EVA Momentum has moved slightly higher for the global Technology sector YTD, driven predominantly by improvements in growth for the Communications Equipment and Electrical Equipment industries. The Semiconductor and Software
industries have both seen a decline in EVA growth, but significantly, both have the highest level of economic profitability and EVA Momentum remains positive. At the outset of 2025, we had a positive view for the 1H of the year and a cautious
approach to the 2H.
Amidst a backdrop of negative and pressured sectoral incremental EVA growth for the Consumer Discretionary space, the global Broadline Retail industry has demonstrated both positive and accelerating EVA Momentum. We take a bottom-up approach to analyze the EVA trends of the five largest names in the industry and explore the historical EVA Margin and EBITDAR Margin estimates for these firms to see how EVA Estimates have fared in the past.
Large Cap firms look unattractive in the PRVit framework with relatively strong levels of Risk-Adjusted Profitability being offset by high Valuation. In contrast, Small Cap firms have better average PRVit scores (vs the Large Cap firms) as observed in the sector’s Mid-Year Review that was published last week.
The industry has seen a sustained deterioration in EVA Fundamentals amidst large cap luxury companies reporting weaker consumer demand across key markets: China, Europe, and North America. EVA Momentum (growth) remains pressured on weak top-line growth and contracting P&L profitability.
We identify attractive names in the Russell 1000 Index with strong growth scores (Profitability Trend, P2), attractive PRVit, and strong ESG Performance Scores. We also include updates on 3 previous reports.
PRVit spreads were positive in AxJ, the Emerging Markets, and the Global universe through the third week of July. Quality stopped working everywhere. Cheap Value outperformed expensive Value in all regions.
We saw the Value trade pick up in June and this has been the story of July so far. The Chart of the Week shows cheap firms outperforming expensive firms across all regions. On the flip side, Quality (P-R) stopped working in June and that has continued through July, with all regions seeing negative spreads for Quality. See this week’s Quant Corner for more results.
Information posted on IBKR Campus that is provided by third-parties does NOT constitute a recommendation that you should contract for the services of that third party. Third-party participants who contribute to IBKR Campus are independent of Interactive Brokers and Interactive Brokers does not make any representations or warranties concerning the services offered, their past or future performance, or the accuracy of the information provided by the third party. Past performance is no guarantee of future results.
This material is from ISS EVA and is being posted with its permission. The views expressed in this material are solely those of the author and/or ISS EVA and Interactive Brokers is not endorsing or recommending any investment or trading discussed in the material. This material is not and should not be construed as an offer to buy or sell any security. It should not be construed as research or investment advice or a recommendation to buy, sell or hold any security or commodity. This material does not and is not intended to take into account the particular financial conditions, investment objectives or requirements of individual customers. Before acting on this material, you should consider whether it is suitable for your particular circumstances and, as necessary, seek professional advice.
Related Articles
Join The Conversation
For specific platform feedback and suggestions, please submit it directly to our team using these instructions.
If you have an account-specific question or concern, please reach out to Client Services.
We encourage you to look through our FAQs before posting. Your question may already be covered!